ALNY — ALNYLAM PHARMACEUTICALS, INC.

—
Nasdaq · Health Care · Pharmaceuticals · CIK 1178670 ·
Last close
$156.50
Market Cap
$20.96B
52W High
$479.79
52W Low
$149.18
ADV30
2,650,139
Next earnings
2026-10-29

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 1,458,086,000 1,096,336,000 345,798,000 2,167,335,000 7,994,672,000 1,754,340,000 4,390,820,000
Jun 2026 1,290,948,000 992,497,000 231,441,000 164,494,000 5,558,769,000 1,708,318,000 4,204,651,000
Mar 2026 1,167,175,000 956,053,000 268,636,000 205,991,000 5,129,547,000 1,710,779,000 4,054,167,000
Dec 2025 1,097,033,000 829,310,000 131,718,000 186,419,000 4,966,331,000 1,657,250,000 4,177,155,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$901,768,000
Investing CF
$-737,903,000
Financing CF
$115,619,000
CapEx
$-149,637,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$19.26
As of
2026-11-01

Balance + Analyst (yfinance extras)

Retained Earnings
$-4,164,704,000
Inventory
$105,907,000
Receivables
$1,084,905,000
ST Investments
$1,832,915,000
EBIT TTM
$1,221,452,000
Pretax Income TTM
$856,406,000
Interest Exp TTM
$365,046,000
Analysts
27

Yahoo Snapshot (yfinance, live)

Total Revenue
$5,013,241,856
EBITDA
$1,033,027,008
Free Cash Flow
$327,232,512
Enterprise Value
$21,509,302,272
Total Cash
$3,587,255,040
Total Debt
$2,996,858,112
Shares Out
133,937,576
Trailing EPS
$19.80
Book Value
$26.92
ROE
138.1%
ROA
9.5%
Div Yield
0.00%

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 3,713,937,000 501,578,000 313,747,000 4,966,331,000 4,177,155,000 789,176,000 524,080,000
Dec 2024 2,248,243,000 -176,885,000 -278,157,000 4,239,983,000 4,172,895,000 67,088,000 -8,312,000
Dec 2023 1,828,292,000 -282,175,000 -440,242,000 3,829,880,000 4,050,524,000 -220,644,000 104,156,000
Dec 2022 1,037,418,000 -785,072,000 -1,131,156,000 3,546,359,000 3,704,582,000 -158,223,000 -541,274,000

TTM Snapshot

Revenues TTM
$4,804,182,000
NetIncome TTM
$807,988,000
OpCashFlow TTM
—
Assets (Latest)
$5,558,769,000
Forward EPS
$11.41

Max Pain — expiry 2026-12-18

max pain strike: $185.00 · spot: $149.40 · call oi: 4,330 · put oi: 5,174
Expected Move to 2026-12-18: ±$16.80 (11.24%) — implied range $132.60 – $166.20 · ATM straddle on $150.00 strike

Peers — same industry

TickerNameMarket CapLastDaily %
VTRS Viatris Inc $23.45B $20.45 —
ASND Ascendis Pharma A/S $17.84B $271.19 —
UTHR UNITED THERAPEUTICS Corp $24.88B $584.10 —
INSM INSMED Inc $26.73B $121.86 —
ROIV Roivant Sciences Ltd. $28.05B $38.71 —

News headlines (Yahoo Finance, 1h cache)

Alnylam Stock Trades Below Its Pre-$1 Billion Buyback Price
2026-11-17 19:45 · Yahoo
What Is Driving Alnylam Stock?
2026-11-16 21:03 · Yahoo
What Moved Alnylam Stock?
2026-11-12 15:13 · Yahoo
RNA Interference (RNAi) - Global Strategic Business Report: Capture the US$8 Billion 2032 Market as Alnylam Pharmaceuticals, Ionis Pharmaceuticals, Qiagen, Benitec BioPharma, and Silence Therapeutics
2026-11-12 14:06 · Yahoo
Alnylam Collaborator Regeneron Advances CIDEBsiRNA with Promising First-in-Human Results in Patients with MASLD
2026-11-10 15:00 · Yahoo
Alnylam Announces Five-Year HELIOS-B Data Demonstrating Sustained Benefit of AMVUTTRA® (vutrisiran) in ATTR-CM
2026-11-09 15:50 · Yahoo
Lilly, Hims reach GLP-1 deal; Alnylam sales chief to step down
2026-11-06 13:13 · Yahoo
Alnylam Announces $1 Billion Share Repurchase Program and Change in Commercial Leadership
2026-11-04 22:15 · Yahoo
Tax-loss selling candidates: the worst-performing US large caps of 2026
2026-11-04 19:47 · Yahoo
Alnylam to Webcast Presentation at the Jefferies Global Healthcare Conference
2026-11-04 13:00 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.